www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

 
Home> Latest News

Chinese pharma companies look West

Updated: 2013-05-20 07:38
By Liu Jie in Beijing and Cecily Liu in London ( China Daily)
Comments() Print Mail Large Medium  Small 分享按鈕 0

Chinese pharma companies look West

Zhejiang Hisun Pharmaceutical Co's pavilion at a fair in Beijing. By setting up a joint venture with US-based Pfizer Inc in September, Hisun made a breakthrough in China's pharmaceutical industry by taking a controlling stake in the JV with Pfizer, the world's largest drug-maker by sales. [Photo/China Daily]

Many seek partnerships, mergers and acquisitions to build brands

Several Chinese pharmaceutical companies have been recognized by the overseas medical industry largely because of their partnerships with multinational giants.

Zhejiang Hisun Pharmaceutical Co set up a joint venture with US-based Pfizer Inc in September 2012. Simcere Pharmaceutical Group has established a partnership with MSD - known as Merck & Co in the US and Canada - and Bristol-Myers Squibb Co. Chinese biotech company Sino Biological Inc reached an agreement with Life Technologies Corp for protein product distribution and development worldwide. Shanghai Fosun Pharmaceutical (Group) Co has become the largest single shareholder of US-based medical care company Saladax Biomedical Inc.

Insiders say the collaborations are mainly driven by foreign drug-makers' desire to leverage their Chinese counterparts' distribution networks, local market knowledge and administrative resources to take a bigger market share, especially in the grassroots sector in China.

"On the flipside, the Chinese companies are also ambitious. They are eager to get international market access, realize technical upgrades and even build their brands through platforms abroad," said Zhang Fabao, a member of China Pharmaceutical Technology Organization Expert Committee.

Chinese pharma companies look West

"That can be seen as a shortcut for Chinese pharmaceutical enterprises to go global and a win-win strategy for both sides," he added.

Bilateral partnership

Hisun got a breakthrough in China's pharmaceutical industry by taking a controlling stake in the joint venture with Pfizer, the world's largest drug-maker by sales. Hisun has a 51 percent share in Hisun-Pfizer Pharmaceuticals Co, with a total investment of $295 million and registered capital of $250 million. Pfizer holds the remaining stock.

The joint venture focuses on the manufacturing and commercialization of branded generics, or high-quality and low-price off-patent medicines, in China and around the world. Hisun contributed a strong portfolio - 75 products, wide market reach in China and expertise in the production and commercialization of generics, while Pfizer offers, in addition to eight products, its research and development, marketing and manufacturing capabilities.

The operational revenue of the joint venture is exected to exceed $2 billion yuan, said Wu Xiaobin, country manager of Pfizer China.

Previous Page 1 2 3 Next Page

Survey & Comments

| About us | Contact |

Constructed by Chinadaily.com.cn

Copyright @ 2012 Ministry of Culture, P.R.China. All rights reserved

主站蜘蛛池模板: 一级做a爰全过程免费视频毛片 | 怡红院亚洲怡红院首页 | 色综合精品 | 亚洲国产欧美一区 | 2021国产精品自拍 | 久久久久久国产精品免费免 | 一级做a爰片性色毛片中国 一级做a爰性色毛片 | 日韩一级欧美一级 | 毛片一级免费 | 一级美国片免费看 | 成年片免费网址网站 | 日本波多野结衣在线 | 亚洲美女爱爱 | 亚洲精品国产专区91在线 | 国产欧美日韩成人 | 精品国产自在在线在线观看 | 日本三级成人午夜视频网 | 成人国产三级精品 | 91久久亚洲精品国产一区二区 | 高清欧美一级在线观看 | 中文字幕亚洲综合久久男男 | 美女与男人对肌免费网站 | 亚洲视频免费在线看 | 成人在线a| 亚洲国产精品a在线 | 男人好大好硬好爽免费视频 | 玖玖精品视频在线观看 | 99re66热这里只有精品免费观看 | 九九99九九视频在线观看 | 久久久久久久久一次 | 午夜美女久久久久爽久久 | 91精品国产91热久久久久福利 | 黄色美女视频网站 | 精品国产精品久久一区免费式 | 欧美一级毛片欧美毛片视频 | 精品国产一区二区三区在线 | 精品国产一区二区 | 99精品热女视频专线 | 99久久精品免费看国产免费软件 | a级毛片无码免费真人 | 欧美高清亚洲欧美一区h |